|
Malignant neoplasm of breast
|
0.340 |
Biomarker
|
disease |
BEFREE |
Synergistic effect of granzyme B-azurin fusion protein on breast cancer cells.
|
30937652 |
2019 |
|
Malignant neoplasm of breast
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
Granzyme B production by activated B cells derived from breast cancer-draining lymph nodes.
|
31357083 |
2019 |
|
Breast Carcinoma
|
0.340 |
Biomarker
|
disease |
BEFREE |
Synergistic effect of granzyme B-azurin fusion protein on breast cancer cells.
|
30937652 |
2019 |
|
Breast Carcinoma
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
Granzyme B production by activated B cells derived from breast cancer-draining lymph nodes.
|
31357083 |
2019 |
|
Malignant neoplasm of breast
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of the actin response by knocking down CDC42 or N-WASP led to a significant increase in granzyme B levels in target cells and was sufficient to convert resistant breast cancer cell lines into a highly susceptible phenotype.
|
30104240 |
2018 |
|
Breast Carcinoma
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of the actin response by knocking down CDC42 or N-WASP led to a significant increase in granzyme B levels in target cells and was sufficient to convert resistant breast cancer cell lines into a highly susceptible phenotype.
|
30104240 |
2018 |
|
Malignant neoplasm of breast
|
0.340 |
Biomarker
|
disease |
CTD_human |
Our data suggest that reduction in the proportion of gammadelta T cells and granzyme B gene polymorphism leads to defective immune function in breast cancer patients.
|
19446661 |
2009 |
|
Malignant neoplasm of breast
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that reduction in the proportion of gammadelta T cells and granzyme B gene polymorphism leads to defective immune function in breast cancer patients.
|
19446661 |
2009 |
|
Breast Carcinoma
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that reduction in the proportion of gammadelta T cells and granzyme B gene polymorphism leads to defective immune function in breast cancer patients.
|
19446661 |
2009 |
|
Breast Carcinoma
|
0.340 |
Biomarker
|
disease |
CTD_human |
Our data suggest that reduction in the proportion of gammadelta T cells and granzyme B gene polymorphism leads to defective immune function in breast cancer patients.
|
19446661 |
2009 |
|
Mammary Neoplasms
|
0.330 |
AlteredExpression
|
group |
BEFREE |
In immunocompetent mouse 4T1 breast tumor model, intratumoral delivery of rAd.sT inhibited both tumor growth and lung metastases. rAd.sT downregulated the expression of several transforming growth factor β (TGFβ) target genes involved in tumor growth and metastases, inhibited Th2 cytokine expression, and induced Th1 cytokines and chemokines, and granzyme B and perforin expression. rAd.sT treatment also increased the percentage of CD8<sup>+</sup> T lymphocytes, promoted the generation of CD4<sup>+</sup> T memory cells, reduced regulatory T lymphocytes (Tregs), and reduced bone marrow-derived suppressor cells.
|
31126191 |
2019 |
|
Mammary Neoplasms
|
0.330 |
Biomarker
|
group |
BEFREE |
Our findings underscore the need to investigate the function of GZMB<sup>+</sup> B cells in breast tumor immunity.
|
31357083 |
2019 |
|
Mammary Neoplasms
|
0.330 |
Biomarker
|
group |
BEFREE |
Administration (intravenous, tail vein) of GrB/4D5/26 to mice bearing BT474 M1 breast tumors resulted in significant tumor suppression.
|
23493312 |
2013 |
|
Mammary Neoplasms
|
0.330 |
Biomarker
|
group |
CTD_human |
Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients.
|
19446661 |
2009 |
|
Autistic Disorder
|
0.300 |
Biomarker
|
disease |
CTD_human |
Altered gene expression and function of peripheral blood natural killer cells in children with autism.
|
18762240 |
2009 |
|
Drug Allergy
|
0.300 |
Biomarker
|
group |
CTD_human |
Fulminant liver failure after vancomycin in a sulfasalazine-induced DRESS syndrome: fatal recurrence after liver transplantation.
|
19706026 |
2009 |
|
Hepatitis
|
0.300 |
Biomarker
|
group |
CTD_human |
Fulminant liver failure after vancomycin in a sulfasalazine-induced DRESS syndrome: fatal recurrence after liver transplantation.
|
19706026 |
2009 |
|
Mammary Neoplasms, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients.
|
19446661 |
2009 |
|
Mammary Carcinoma, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients.
|
19446661 |
2009 |
|
Vitiligo
|
0.120 |
GeneticVariation
|
disease |
BEFREE |
Our positive results provide additional supportive evidence that GZMB gene is an important locus for vitiligo in Han Chinese population.
|
30158536 |
2018 |
|
Vitiligo
|
0.120 |
Biomarker
|
disease |
BEFREE |
The inflammatory cytotoxic markers such as Granzyme B and Perforin were also elevated in vitiligo and halo nevus, suggesting inflammatory responses in situ.
|
28385330 |
2017 |
|
Vitiligo
|
0.120 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants.
|
27723757 |
2016 |
|
Vitiligo
|
0.120 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo.
|
22561518 |
2012 |
|
Vitiligo
|
0.120 |
GeneticVariation
|
disease |
GWASCAT |
Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo.
|
20410501 |
2010 |
|
Vitiligo
|
0.120 |
GeneticVariation
|
disease |
GWASDB |
Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo.
|
20410501 |
2010 |